United Therapeutics (NASDAQ:UTHR) PT Raised to $300.00

United Therapeutics (NASDAQ:UTHR) had its price target upped by equities research analysts at JPMorgan Chase & Co. from $280.00 to $300.00 in a note issued to investors on Tuesday, Benzinga reports. The brokerage presently has an “overweight” rating on the biotechnology company’s stock. JPMorgan Chase & Co.‘s price objective suggests a potential upside of 8.52% from the stock’s current price.

Other analysts have also recently issued reports about the stock. StockNews.com upgraded shares of United Therapeutics from a “buy” rating to a “strong-buy” rating in a research note on Thursday, May 16th. Oppenheimer boosted their price objective on shares of United Therapeutics from $375.00 to $400.00 and gave the company an “outperform” rating in a report on Thursday, May 2nd. Wells Fargo & Company lifted their target price on United Therapeutics from $309.00 to $325.00 and gave the stock an “overweight” rating in a report on Thursday, March 7th. Leerink Partnrs reiterated an “outperform” rating on shares of United Therapeutics in a report on Monday, February 5th. Finally, The Goldman Sachs Group raised their price target on shares of United Therapeutics from $218.00 to $240.00 and gave the stock a “neutral” rating in a research report on Friday, May 3rd. One equities research analyst has rated the stock with a hold rating, nine have given a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat, United Therapeutics currently has a consensus rating of “Buy” and an average target price of $309.44.

United Therapeutics Stock Performance

Shares of UTHR stock opened at $276.44 on Tuesday. The company has a current ratio of 3.77, a quick ratio of 3.64 and a debt-to-equity ratio of 0.04. The company has a market cap of $12.26 billion, a PE ratio of 13.07 and a beta of 0.54. United Therapeutics has a 12-month low of $204.44 and a 12-month high of $279.98. The business’s fifty day simple moving average is $245.78 and its 200-day simple moving average is $233.38.

United Therapeutics (NASDAQ:UTHR) last announced its earnings results on Wednesday, May 1st. The biotechnology company reported $6.17 earnings per share (EPS) for the quarter, beating the consensus estimate of $5.63 by $0.54. The company had revenue of $677.70 million for the quarter, compared to analyst estimates of $620.31 million. United Therapeutics had a return on equity of 18.72% and a net margin of 42.05%. The firm’s quarterly revenue was up 33.7% compared to the same quarter last year. During the same period in the prior year, the company posted $4.86 EPS. Analysts expect that United Therapeutics will post 24.2 earnings per share for the current fiscal year.

Insider Activity

In related news, Director Martine A. Rothblatt sold 1,468 shares of the stock in a transaction on Tuesday, May 21st. The shares were sold at an average price of $275.85, for a total transaction of $404,947.80. Following the sale, the director now directly owns 130 shares of the company’s stock, valued at $35,860.50. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. In other news, Director Nilda Mesa sold 325 shares of the stock in a transaction that occurred on Wednesday, March 27th. The stock was sold at an average price of $237.80, for a total transaction of $77,285.00. Following the transaction, the director now owns 5,373 shares in the company, valued at approximately $1,277,699.40. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Also, Director Martine A. Rothblatt sold 1,468 shares of the business’s stock in a transaction on Tuesday, May 21st. The stock was sold at an average price of $275.85, for a total transaction of $404,947.80. Following the completion of the sale, the director now directly owns 130 shares of the company’s stock, valued at approximately $35,860.50. The disclosure for this sale can be found here. Insiders sold a total of 155,208 shares of company stock valued at $37,436,641 in the last three months. 12.50% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On United Therapeutics

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Vanguard Group Inc. lifted its stake in United Therapeutics by 0.4% in the 3rd quarter. Vanguard Group Inc. now owns 4,662,911 shares of the biotechnology company’s stock valued at $1,053,212,000 after buying an additional 20,373 shares in the last quarter. Dimensional Fund Advisors LP lifted its position in shares of United Therapeutics by 1.8% in the fourth quarter. Dimensional Fund Advisors LP now owns 561,950 shares of the biotechnology company’s stock valued at $123,566,000 after acquiring an additional 9,962 shares in the last quarter. LSV Asset Management boosted its stake in shares of United Therapeutics by 40.3% in the first quarter. LSV Asset Management now owns 529,519 shares of the biotechnology company’s stock worth $121,641,000 after acquiring an additional 152,151 shares during the last quarter. Norges Bank purchased a new stake in shares of United Therapeutics during the fourth quarter worth approximately $100,519,000. Finally, Swedbank AB purchased a new stake in shares of United Therapeutics during the first quarter worth approximately $97,316,000. 94.08% of the stock is owned by hedge funds and other institutional investors.

United Therapeutics Company Profile

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.